Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer by Jantus Lewintre, Eloisa
DOI:10.1093/jnci/djt205
Advance Access publication August 12, 2013
JNCI | Articles 1385
© The Author 2013. Published by Oxford University Press. All rights reserved. 
For Permissions, please e-mail: journals.permissions@oup.com.
jnci.oxfordjournals.org
Article
investigation of complement Activation Product c4d as a 
Diagnostic and Prognostic Biomarker for lung cancer
Daniel Ajona, María J. Pajares, Leticia Corrales, Jose L. Perez-Gracia, Jackeline Agorreta, Maria D. Lozano, Wenceslao Torre, 
Pierre P. Massion, Juan P. de-Torres, Eloisa Jantus-Lewintre, Carlos Camps, Javier J. Zulueta, Luis M. Montuenga, Ruben Pio
Manuscript received January 3, 2013; revised May 24, 2013; accepted May 28, 2013.
Correspondence to: Luis M.  Montuenga, Division of Oncology, CIMA Building, Pio XII 55, 31008 Pamplona, Spain (e-mail: lmontuenga@unav.es) or 
Ruben Pio, Division of Oncology, CIMA Building, Pio XII 55, 31008 Pamplona, Spain (e-mail: rpio@unav.es).
 Background There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of 
complement activation fragments.
 Methods We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degra-
dation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage 
supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma 
samples from advanced (n = 50) and early lung cancer patients (n = 84) subjects with inflammatory lung diseases 
(n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program 
(n = 190). Two-sided P values were calculated by Mann–Whitney U test.
 Results Lung cancer cells activated the classical complement pathway mediated by C1q binding that was inhibited 
by phosphomonoesters. Survival was decreased in patients with high C4d deposition in tumors (hazard ratio 
[HR] = 3.06; 95% confidence interval [CI] = 1.18 to 7.91). C4d levels were increased in bronchoalveolar lavage 
fluid from lung cancer patients compared with patients with nonmalignant respiratory diseases (0.61 ± 0.87 vs 
0.16 ± 0.11 µg/mL; P < .001). C4d levels in plasma samples from lung cancer patients at both advanced and early 
stages were also increased compared with control subjects (4.13 ± 2.02 vs 1.86 ± 0.95 µg/mL, P < 0.001; 3.18 ± 3.20 
vs 1.13 ± 0.69 µg/mL, P < .001, respectively). C4d plasma levels were associated with shorter survival in patients at 
advanced (HR = 1.59; 95% CI = 0.97 to 2.60) and early stages (HR = 5.57; 95% CI = 1.60 to 19.39). Plasma C4d levels 
were reduced after surgical removal of lung tumors (P < .001) and were associated with increased lung cancer 
risk in asymptomatic individuals with (n = 32) or without lung cancer (n = 158) (odds ratio = 4.38; 95% CI = 1.61 to 
11.93).
 Conclusions Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer.
  J Natl Cancer Inst;2013;105:1385–1393
Lung cancer is the leading cause of cancer death worldwide 
(1). The US National Lung Screening Trial demonstrated that 
computed tomography (CT) screening reduces lung cancer 
mortality (2). In this context, the use of biomarkers may help in 
the implementation of population-based screening programs. 
Biomarkers could be used to identify populations at increased risk, 
to confirm the presence of malignant cells, or to monitor response 
to treatment. Numerous molecular markers have been proposed 
(3). Unfortunately, genetic heterogeneity has limited the success 
of these initiatives and, to date, no diagnostic marker has proven 
useful in lung cancer clinical practice. To overcome this limitation, 
an alternative approach would be to look not for cancer but for the 
immune response to cancer (4). Immune activation may generate 
host-derived markers more homogeneous than cancer-derived 
markers. Immune responses against intracellular and surface 
tumor antigens are well documented in patients with lung cancer 
(5). In particular, the complement system is activated in lung 
tumor cells (6–9). Complement is a central component of innate 
immunity that plays an essential role in immune surveillance and 
homeostasis (10). In the past years, our group has evaluated the role 
of complement in the control of lung cancer cell growth (9,11–13). 
We have recently reported that lung cancer cells produce C5a, 
a potent proinflammatory mediator that creates a favorable 
microenvironment for lung cancer progression (14). However, the 
pathway by which lung cancer cells activate complement and the 
value of complement activation fragments as diagnostic biomarkers 
remain unclear.
In this study, we dissected the mechanisms by which comple-
ment is activated in lung cancer cells and evaluated the diagnostic 
performance of molecules released during complement activation. 
Our results indicate that lung tumors activate the classical com-
plement pathway and generate C4d, a degradation product of this 
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pathway. Moreover, our results suggest that the determination of 
C4d may be of value for the diagnosis and prognosis of lung cancer.
Methods
Patient Samples
Clinical specimens were obtained at the Clinica Universidad 
de Navarra and the Hospital General Universitario de Valencia, 
Spain. Individuals were white. Lung tumors were classified accord-
ing to the World Health Organization 2004 classification and the 
International System for Staging Lung Cancer (15,16). The study 
protocols were approved by the institutional ethical committees, 
and all patients gave written informed consent. Characteristics of 
the cohorts are specified in the Supplementary Methods (available 
online) or have been described previously (17,18).
Experimental Procedures
Details on the materials and the analysis of complement activation, 
immunocytochemical C4d detection and C4d quantification are 
described in the Supplementary Methods (available online).
Statistical Analyses
Normality was assessed using the Shapiro–Wilk test. Normally dis-
tributed data were analyzed using the Student t test. Nonnormally 
distributed data were analyzed using the Mann–Whitney U test, the 
Kruskal–Wallis H test, or the Wilcoxon signed-rank test. The rela-
tionship between variables was analyzed using Spearman rank cor-
relation. Comparison of categorical variables was performed using 
the Pearson χ2 test. Receiver operating characteristic (ROC) curves 
were used to assess the accuracy of the biomarker. Statistically sig-
nificant differences from an area under the ROC curve of 0.5 were 
calculated with a z score test. Survival curves were generated using 
the Kaplan–Meier method, and statistically significant differences 
were analyzed with the log rank test. Multivariable analyses were 
performed with the Cox proportional hazards model. Statistically 
significant variables from the univariable analyses and variables 
likely to affect the outcome (eg, smoking status) were entered into 
the multivariable Cox analysis. The proportional hazards assump-
tion was examined by testing interactions between the covariables 
of the final model and time. A conditional logistic regression model 
was performed to estimate odds ratios (ORs) and 95% confidence 
intervals (CIs) for lung cancer risk, adjusting for age, sex, and smok-
ing status. Age and pack-years were dichotomized using the median 
value. All statistical tests were two-sided, and P values less than .05 
were considered statistically significant. The conditional logistic 
regression model was performed used Logistic 1.36 (Jerusalem, 
Israel). All other statistical analyses were performed with SPSS 15.0 
(Chicago, IL).
results
Complement Activation in Lung Cancer Cells  
and Bronchial Epithelial Cells
Complement activation was determined in human lung cancer 
and bronchial epithelial cell lines (19) by measuring C3 deposition 
after incubation with normal human serum (NHS). A statistically 
significant increase in the ratio of C3 deposition was observed 
in lung cancer cells compared with bronchial epithelial cells 
(9.72 ± 4.29 vs 2.58 ± 0.29; P = .008) (Figure 1A).
There are three pathways of complement activation. The clas-
sical pathway is initiated by C1q binding; the lectin pathway is ini-
tiated by the binding of mannose binding lectin to carbohydrate 
moieties; and the alternative pathway is initiated by the sponta-
neous cleavage of C3 and its binding to factor B.  The classical 
and lectin complement pathways require the presence of calcium 
(Ca2+) and magnesium (Mg2+) ions, whereas the alternative path-
way requires only magnesium ions. To determine which comple-
ment pathway was activated in lung cancer cells, C3 deposition 
was measured in A549 and H157 cells incubated with NHS in the 
presence of: Ca2+ and Mg2+ (to allow complement activation by all 
three pathways), EDTA (to prevent complement activation), or 
EGTA/Mg2+ (to prevent classical and lectin pathway activation). 
C1q-depleted serum (to prevent classical pathway activation) or 
factor B-depleted serum (to prevent alternative pathway activation) 
were also used (Figure 1B). When EGTA/Mg2+ or C1q-depleted 
serum was used, no complement activation was observed, pointing 
to a dominant role of the classical pathway. Incubation with factor 
B–depleted serum resulted in a partial reduction of C3 deposition, 
suggesting a role of the alternative pathway amplification loop. 
Mannose binding lectin did not bind to lung cancer cells, ruling 
out the participation of the lectin pathway (data not shown). C1q 
binding was assessed to confirm the involvement of the classical 
pathway (Figure 1B). C1q binding was prevented in the presence 
of EGTA/Mg2+, whereas it was not affected by the use of factor B–
depleted serum. Moreover, incubation with peptide 2J, a molecule 
that inhibits the function of C1q (20), markedly reduced C3 depo-
sition (Figure 1C).
We next evaluated the binding of C1q and the deposition of 
C4d, a degradation product of the classical pathway, in a panel of 
bronchial epithelial and lung cancer cell lines. C1q binding and 
C4d deposition were markedly increased in lung cancer cells when 
compared with bronchial epithelial cells (P  =  .04 and P  =  .008, 
respectively) (Figure 1D). Furthermore,  in the cell panel indicated 
above, C4d deposition was statistically significantly correlated with 
C3 deposition (Spearman correlation coefficient = 0.93; P < .001) 
and C1q binding (Spearman correlation coefficient = 0.65; P = .03) 
(Supplementary Figure  1, available online). These data indicate 
that the classical pathway plays an essential role in complement 
activation in lung cancer cells.
Role of C1q in the Activation of Complement in Lung 
Cancer Cells
The classical complement pathway can be initiated by C1q binding 
to antigen-bound antibodies or to distinct molecular structures 
in an antibody-independent manner. To determine whether the 
activation of the classical pathway was mediated by a direct binding 
of C1q, C3 deposition was measured in A549 and H157 cells 
preincubated with C1q and treated with C1q-depleted serum after 
removal of the unbound C1q. Under these experimental conditions, 
cancer cells deposited C3, indicating that C1q directly binds to 
lung cancer cells and activates the classical pathway (Figure 2A). 
Because membrane phospholipids can play a role in the interaction 
of C1q with the cell surface (21), we examined the effect of 
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phosphomonoesters on the binding of C1q to lung cancer cells. 
A549 and H157 cells were incubated with NHS in the presence 
of phosphoserine, phosphocholine, or phosphoethanolamine. All 
three compounds inhibited C1q binding and C3 deposition in a 
dose-dependent manner (Figure 2B).
Activation of the Classical Complement Pathway  
in Primary Lung Tumors
To determine whether classical pathway activation occurs in 
primary lung tumors, we analyzed the presence of C4d in 90 
non–small cell lung tumors. C4d is an inactive split product 
of complement activation used as a trace of classical pathway 
activation (22). An immunohistochemical analysis showed positive 
staining for C4d, indicating that the classical complement pathway 
is activated in primary lung tumor cells (Figure  3A). Some C4d 
deposition was also observed in stromal cells of the tumor 
microenvironment. Specifically, there was immunoreactivity 
in neutrophils and plasma cells in one-third of the tumors. In a 
small number of specimens, some fibroblasts and lymphocytes 
also showed immunoreactivity. Adenocarcinomas showed higher 
levels of C4d deposition than squamous cell carcinomas (125 ± 49 
vs 88 ± 42; P = .001) (Supplementary Table 1, available online). C4d 
levels were also statistically significantly associated with smoking 
status (P = .03) and tumor stage (P = .001) (Supplementary Table 1, 
available online). No association was detected with age, sex, or 
tobacco consumption (pack-years). Interestingly, overall survival 
was statistically significantly decreased in patients with high C4d 
deposition (P  =  .01) (Figure  3B). Multivariable analysis, adjusted 
for sex, smoking status and stage, showed that increased C4d 
immunoreactivity was an independent prognostic factor for overall 
Figure  1. Complement activation in lung cancer cells. A) Deposition 
of complement C3-derived fragments after complement activation in 
bronchial epithelial cells (white bars) and in lung cancer cell lines (black 
bars). B) C3 deposition and C1q binding in A549 and H157 lung cancer 
cells after activation of complement using normal human serum (NHS; 
at different buffer conditions) or depleted sera (factor B [FB]–depleted 
serum or C1q-depleted serum). C) C3 deposition in A549 and H157 cells 
after exposure to NHS in the presence of the C1q blocking peptide 2J 
(1 mM). D) Binding of C1q and C4d deposition in bronchial epithelial 
cell lines (white bars) and in lung cancer cell lines (black bars) after 
incubation with NHS. In all graphs, data are expressed as the ratio of 
the mean fluorescence intensity (MFI) between cell incubated with 10% 
serum and cells incubated with its respective complement inactivated 
serum. A ratio of 1 means no complement activation (horizontal line). 
All bar graphs in the figure show mean ± standard deviation (from at 
least three independent experiments). Statistically significant differ-
ences between bronchial and tumor cells were analyzed using the two-
sided Mann–Whitney U test.
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survival (hazard ratio [HR] =3.06; 95% CI = 1.18 to 7.91; P = .02) 
in patients with lung cancer.
C4d Levels in Bronchoalveolar Lavage Fluid From Lung 
Cancer Patients
We next evaluated whether the levels of C4d may be increased 
in bronchoalveolar lavage supernatants from patients with 
lung cancer (n = 50) compared with those from patients with 
nonmalignant lung diseases (n  =  22). C4d concentration was 
higher in bronchoalveolar lavage fluid from patients with 
lung cancer than in that from noncancer patients (0.61 ± 0.86 
vs 0.16 ± 0.11  µg/mL; P < .001) (Figure  4A). C4d was 
associated with smoking status in the cancer group (P  =  .04) 
(Supplementary Table  2, available online). No association 
was found with sex, age, tobacco consumption, or histology 
(Supplementary Table  2, available online). A ROC curve was 
generated to assess the performance of the marker (Figure 4B). 
The area under the ROC curve was 0.726 (95% CI = 0.610 to 
0.843; P  =  .002). This study demonstrated that airway fluids 
from lung cancer patients contain higher concentrations of the 
complement fragment C4d than airway fluids from patients 
with benign lung diseases.
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Figure  2. Role of C1q on complement activation in lung cancer cells. 
A) A549 and H157 cells were preincubated with purified human C1q 
(15 µg/mL) or phosphate-buffered saline (PBS), washed, treated with C1q-
depleted serum, and analyzed for C3 deposition. Cells incubated with nor-
mal human serum (NHS) were used as a positive control. Data are shown 
as mean ± standard deviation of three independent experiments expressed 
as the ratio of the mean fluorescence intensity (MFI) between serum and 
its respective complement inactivated serum. A horizontal line crossing 
the y-axis at 1 indicates the ratio when there is no complement activation. 
B) A549 and H157 cells were incubated with NHS in the presence of increas-
ing concentrations of phosphoserine, phosphocholine, or phosphoe-
thanolamine and tested for C3 deposition and C1q binding. Complement 
activity in the absence of phosphomonoesters was set at 100%. Data show 
a representative result from three independent experiments.
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Plasma C4d Levels in Lung Cancer Patients  
at Advanced Stages
To assess whether C4d generated in the local tumor microenvi-
ronment enters the circulation, C4d concentration was meas-
ured in plasma samples from 50 lung cancer patients at advanced 
stages and compared with that in 50 control subjects matched by 
sex, age, and smoking consumption. Plasma samples from lung 
cancer patients had statistically significantly higher levels of C4d 
than those from control subjects (4.13 ± 2.02 vs 1.86 ± 0.95 µg/mL; 
P < .001) (Figure 5A). No statistically significant association was 
found between C4d levels and sex, age, smoking history, histol-
ogy, or stage, except for tobacco consumption in the control group 
(P  =  .049) (Supplementary Table  3, available online). The area 
under the ROC curve was 0.856 (P < .001) (Figure 5B).
To evaluate the association of C4d levels with the prognosis 
of lung cancer patients, plasma C4d concentration was measured 
in an independent cohort of 83 advanced lung cancer patients for 
which clinical follow-up data were available. C4d levels in this 
cohort were 3.42 ± 1.94 µg/mL. The concentration of the marker 
was not associated with sex, age, histology, or stage (Supplementary 
Table  4, available online). Patients with high plasma C4d levels 
(>3  μg/mL) had statistically significantly worse overall survival 
(P = .049) (Figure 5C). In a multivariable analysis adjusted for age 
and stage, the hazard ratio for advanced lung cancer patients with 
high C4d levels was 1.593 (95% CI = 0.974 to 2.604; P = .06).
Plasma C4d Levels in Patients With Inflammatory  
Lung Diseases
We explored the potential confounding effect of conditions 
associated with pulmonary inflammation. We used control subjects 
(n = 43) and patients with emphysema (n = 44), chronic obstructive 
pulmonary disease (n  =  44), or both (n  =  45). All groups were 
matched by sex, age, and smoking history. C4d concentration in 
plasma samples from patients with these inflammatory lung diseases 
was not statistically significantly different from that measured in 
control subjects (Figure 5D).
Association of Plasma C4d Levels and Clinical Outcome 
in Patients With Early-Stage Lung Cancer
Because a useful diagnostic biomarker should be able to detect 
the disease at an early stage, plasma C4d levels were measured in 
stage I or II lung cancer patients (n = 84) and control individuals 
(n  =  45) matched by age, sex, and smoking history (pack-years). 
Plasma samples from patients with lung cancer showed statistically 
significantly higher levels of C4d than those from control subjects 
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Figure  3. Complement activation in primary lung tumors. A) Repre-
sentative immunostaining for C4d in two lung cancer specimens, an 
adenocarcinoma (AC) and a squamous cell carcinoma (SCC). Scale 
bar = 50 μm. B) Kaplan–Meier curve for overall survival. Patients were 
stratified into two groups according to the median of the C4d H score 
(≤104 vs >104). The median survival time in the high score group was 
6.5  years and was not reached in the low score group. Differences 
between groups were evaluated using the two-sided log-rank test.
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Figure 4. Complement component C4d in bronchoalveolar lavage fluid 
from patients with lung cancer. A) Quantitation of C4d in bronchoalveo-
lar lavage supernatants from patients with lung cancer and patients with 
nonmalignant respiratory diseases. Mean ± standard deviation is also 
shown. The P value was calculated using the two-sided Mann–Whitney 
U test. B) A receiver operating characteristic curve was generated using 
C4d levels. The area under the curve (AUC) was 0.726 (95% confidence 
interval = 0.610 to 0.843; P = .002, based on a two-sided z score test).
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(3.18 ± 3.20 vs 1.13 ± 0.69 µg/mL; P < .001) (Figure 6A). The area 
under the ROC curve was 0.782 (P < .001) (Figure 6B). Plasma C4d 
levels were statistically significantly correlated with C4d deposition 
in tumor cells (Spearman correlation coefficient = 0.36; P = .03) and 
with tumor size (Spearman correlation coefficient = 0.36; P = .001) 
(Supplementary Figure  2). The correlation between plasma lev-
els and C4d deposition was improved when the C4d H score was 
corrected by tumor diameter (P = .005) (data not shown). Patients 
diagnosed with stage I showed lower C4d plasma levels than those 
diagnosed with stage II (P = .02) (Supplementary Table 5, available 
online). Patients with higher levels of C4d (>3 μg/mL) had a sta-
tistically significantly shorter overall survival than those with low 
C4d levels (P = .002) (Figure 6C). Multivariable analysis, adjusted 
for age, smoking status, and stage, showed that high C4d deposi-
tion was an independent prognostic factor for poor overall survival 
(HR = 5.57; 95% CI = 1.60 to 19.39; P = .007) in early stage lung 
cancer patients.
Plasma C4d Levels After Surgical Removal  
of Lung Tumors
We measured the levels of C4d in paired plasma samples (pre- and 
postsurgery) from 25 lung cancer patients with high (>2 μg/mL) 
C4d levels in the presurgery plasma. Pathological stages of these 
patients were: IA (n = 13), IB (n = 8), IIA (n = 1), IIB (n = 1), and 
IIIA (n = 2). In all but one case, C4d levels were reduced after sur-
gical removal of the tumor (P < .001) (Figure 6D). As expected, in 
19 patients with low plasma C4d levels (<2 μg/mL), the concen-
tration of the marker did not change after resection of the tumor 
(0.76 ± 0.46 vs 0.75 ± 0.27 µg/mL in pre- and postsurgery samples, 
respectively; P = .81 using the two-sided Mann–Whitney U test). 
These results provided evidence that plasma C4d levels depend on 
the presence of the tumor.
Plasma C4d Levels in Asymptomatic Lung  
Cancer Patients
Plasma C4d levels were evaluated in samples from 190 asympto-
matic individuals enrolled in a CT screening program. Thirty-
two of them were diagnosed with lung cancer in the context of 
the program, and the remaining 158 individuals had no evidence 
of cancer after CT screening. Both groups were matched by sex, 
age, and smoking history. Plasma C4d levels were statistically sig-
nificantly higher in individuals with lung cancer than in individu-
als without the disease (1.80 ± 1.36 vs 0.80 ± 0.47 µg/mL; P < .001) 
(Figure 7A). The area under the ROC curve was 0.735 (P < .001) 
(Figure  7B). No association between plasma C4d levels and sex, 
age, or pack-years was found (Supplementary Table  6, available 
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Figure  5. C4d levels in plasma samples from patients with advanced 
lung cancer (stages III and IV). A) Dot plot quantifying C4d in each 
plasma sample. Mean ± standard deviation is also shown. The P values 
were calculated using the two-sided Mann–Whitney U test. B) The area 
under the curve (AUC) was 0.856 (95% confidence interval = 0.782 to 
0.930; P < .001, based on a two-sided z score test). C) Kaplan–Meier curve 
for overall survival in an independent cohort of lung cancer patients at 
advanced stages. Based on the median value of the cohort of patients, 
a cutoff of 3 μg/mL was used to classify patients into high and low C4d 
plasma levels. The statistical significance of the difference was evaluated 
using the two-sided log-rank test. The median survival times in the low 
and high score groups were 10.9 months and 7.3 months, respectively. 
D) Plasma C4d levels in control subjects and in patients with emphy-
sema, chronic obstructive pulmonary disease (COPD), or both. No 
statistically significant differences were found among groups (P = .63; 
two-sided Kruskal–Wallis H test).
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online). In a conditional logistic regression model, C4d levels were 
associated with a statistically significant increase in lung cancer risk 
(OR = 4.38; 95% CI = 1.61 to 11.93; P < .001). This result suggests 
that C4d levels may be of value to predict the risk of lung cancer in 
asymptomatic individuals.
Discussion
The improved knowledge of lung cancer biological alterations 
has not yet led to the development of a cost-effective, sensitive, 
and specific diagnostic biomarker. In this study, we demonstrate 
that lung cancer cells efficiently activate the classical complement 
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pathway. Interestingly, C4d, a stable complement split product, was 
found elevated in malignant lung tissues, bronchoalveolar lavage 
fluid, and plasma from lung cancer patients. Moreover, the levels of 
this marker were associated with disease prognosis.
Several lines of evidence support the role of complement activa-
tion in tumors (23). In the case of lung cancer, we and others have 
demonstrated the capacity of cancer cells to activate complement 
(6–9), but the exact mechanisms underlying this activation have 
remained largely unclear. Here, we demonstrate that lung cancer 
cells activate complement more efficiently than bronchial epithe-
lial cells. In addition, our results indicate that complement activa-
tion in lung cancer cells occurs through the classical pathway. This 
pathway can be triggered upon binding of C1q to a wide range of 
target molecules (21,24,25). The presence of phosphomonoesters 
inhibited C1q binding to lung tumor cells, suggesting that changes 
in the phospholipid composition of lung cancer cell membranes 
may target tumor cells for complement recognition.
Despite complement activation, lung cancer cells are extremely 
resistant to complement-mediated damage due to the expression 
of complement inhibitors (8,9,11,26). In this context, tumor cells 
could take advantage of this complement activation to promote 
tumor progression. This hypothesis would explain our present 
observation that high C4d deposition in malignant cells and high 
plasma C4d levels are associated with poor prognosis in non–small 
cell lung cancer patients. In agreement with this, we have recently 
shown that the complement component C5a is produced by lung 
cancer cells and promotes tumor growth in a murine lung cancer 
model (14). A cancer-promoting effect of complement activation 
has also been reported in other mouse models of cancer (27,28). 
Taken together, these results suggest an association between com-
plement activation and malignant potential in cancer.
The observation that lung cancer cells activate the classical 
complement pathway prompted us to evaluate its utility as a bio-
marker. An analysis of bronchial lavage supernatants and plasma 
samples from lung cancer patients revealed high C4d levels, sug-
gesting that this molecule is released to the extracellular medium 
after classical pathway activation in tumor cells. The correlation 
found between C4d plasma levels and C4d deposition supports this 
conclusion. However, the degree of correlation indicates that other 
factors, such as tumor size, tumor location, or microvascular het-
erogeneity, influence the levels of circulating C4d. Moreover, we 
cannot exclude the participation of the tumor microenvironment 
in the production of C4d or the involvement of extrinsic pathways 
of C4d production. Villanueva et al. described the presence of exo-
proteases in serum from patients with bladder, breast, and pros-
tate cancer and suggested their capacity to generate peptides from 
complement components (29). In any case, the specific determina-
tion of C4d brings about a substantial improvement in diagnostic 
accuracy. In fact, our results support the value of C4d quantifica-
tion, or another method of assessing classical complement acti-
vation, for the early diagnostic or prognostic evaluation of lung 
cancer patients. This conclusion is supported by the use of different 
biological samples (tumor tissue, bronchoalveolar lavage fluid, and 
plasma) and a range of patient cohorts. Further clinical validation 
of our findings may support the clinical use of this marker.
This study has some limitations. Additional validation sets 
are required to establish reliable cutoff values and to evaluate the 
performance of the test in specific clinical applications (eg, in the 
context of a screening program). More research is also required 
to standardize the C4d measurements. The status of the marker 
in other tumor types needs to be evaluated. Results obtained on 
the influence of histology or smoking status are inconclusive and 
deserve a more detailed analysis. Finally, although our data indicate 
that the levels of C4d are not affected by inflammatory pulmonary 
diseases, the impact of other potentially confounding pathologies 
needs to be addressed.
With these limitations in mind, prospective studies are planned 
to translate these findings to the clinic. We are currently in the 
process of evaluating the capacity of the marker to add diagnostic 
information in the classification of indeterminate lung nodules. This 
is especially important in the context of future lung cancer screen-
ing programs. The use of a highly specific marker may help in the 
clinical management of the nodules detected by CT. Our plans are to 
evaluate the effectiveness of the marker in a cohort of prospectively 
collected patients presenting with one or more lung nodules discov-
ered by chest CT. Furthermore, the determination of C4d may be 
potentially useful in the selection of high-risk individuals who need 
to undergo screening, as has already been suggested for other molec-
ular markers (30). We are in the process of validating the predictive, 
diagnostic, and prognostic potential of the marker in a cohort of 
patients and controls from an independent CT screening trial.
In conclusion, we have shown that lung cancer cells efficiently 
promote complement activation by the classical pathway. As a con-
sequence, C4d, a stable complement split product, is increased in 
biological samples from lung cancer patients, is associated with poor 
prognosis, and may be of value for the detection of lung cancer at a 
very early stage. Our data highlight the relationship between lung 
tumors and complement activation and provide new opportunities 
to improve the clinical management of lung cancer patients.
references
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 
2013;63(1):11–30.
 2. Aberle DR, Adams AM, Berg CD, et  al. Reduced lung-cancer mortal-
ity with low-dose computed tomographic screening. N Engl J Med. 
2011;365(5):395–409.
 3. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, 
Massion PP. The state of molecular biomarkers for the early detection of 
lung cancer. Cancer Prev Res (Phila). 2012;5(8):992–1006.
 4. Finn OJ. Immune response as a biomarker for cancer detection and a lot 
more. N Engl J Med. 2005;353(12):1288–1290.
 5. Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for 
non-small cell lung cancer: novel approaches to improve patient outcome. 
J Thorac Oncol. 2011;6(10):1763–1773.
 6. Kay AB, Smith AF, McGavin CR, Tuft SB. Immunoglobulins and comple-
ment in pleural effusions associated with bronchogenic carcinoma. J Clin 
Pathol. 1976;29(10):887–889.
 7. Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. 
Immunoglobulins and complement components levels in patients with 
lung cancer. Rom J Intern Med. 1992;30(1):39–44.
 8. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human 
lung cancer cell lines express cell membrane complement inhibitory pro-
teins and are extremely resistant to complement-mediated lysis; a compari-
son with normal human respiratory epithelium in vitro, and an insight into 
mechanism(s) of resistance. Clin Exp Immunol. 1998;113(2):173–182.
 9. Ajona D, Castano Z, Garayoa M, et al. Expression of complement factor H 
by lung cancer cells: effects on the activation of the alternative pathway of 
complement. Cancer Res. 2004;64(17):6310–6318.
JNCI | Articles 1393jnci.oxfordjournals.org
 10. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a 
key system for immune surveillance and homeostasis. Nat Immunol. 
2010;11(9):785–797.
 11. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation 
of human complement factor H sensitizes non-small cell lung cancer 
cells to complement attack and reduces in vivo tumor growth. J Immunol. 
2007;178(9):5991–5998.
 12. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Non-small cell lung cancer 
cells produce a functional set of complement factor I and its soluble cofac-
tors. Mol Immunol. 2008;45(1):169–179.
 13. Okroj M, Corrales L, Stokowska A, Pio R, Blom AM. Hypoxia increases 
susceptibility of non-small cell lung cancer cells to complement attack. 
Cancer Immunol Immunother. 2009;58(11):1771–1780.
 14. Corrales L, Ajona D, Rafail S, et  al. Anaphylatoxin C5a creates a 
favorable microenvironment for lung cancer progression. J Immunol. 
2012;189(9):4674–4683.
 15. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health 
Organization Classification of Tumours. Pathology and Genetics of Tumours of the 
Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
 16. Mountain CF. Revisions in the International System for Staging Lung 
Cancer. Chest. 1997;111(6):1710–1717.
 17. Pio R, Garcia J, Corrales L, et  al. Complement factor H is elevated in 
bronchoalveolar lavage fluid and sputum from patients with lung cancer. 
Cancer Epidemiol Biomarkers Prev. 2010;19(10):2665–2672.
 18. Jantus-Lewintre E, Sanmartin E, Sirera R, et al. Combined VEGF-A and 
VEGFR-2 concentrations in plasma: diagnostic and prognostic implica-
tions in patients with advanced NSCLC. Lung Cancer. 2011;74(2):326–331.
 19. Sato M, Vaughan MB, Girard L, et  al. Multiple oncogenic changes 
(K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) 
are not sufficient to confer a full malignant phenotype on human bronchial 
epithelial cells. Cancer Res. 2006;66(4):2116–2128.
 20. Roos A, Nauta AJ, Broers D, et  al. Specific inhibition of the clas-
sical complement pathway by C1q-binding peptides. J Immunol. 
2001;167(12):7052–7059.
 21. Kojouharova M, Reid K, Gadjeva M. New insights into the molecu-
lar mechanisms of classical complement activation. Mol Immunol. 
2010;47(13):2154–2160.
 22. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a bio-
marker. Kidney Int. 2012;81(7):628–639.
 23. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the 
complement cascade. Mol Cancer Res. 2010;8(11):1453–1465.
 24. Ghai R, Waters P, Roumenina LT, et  al. C1q and its growing family. 
Immunobiology. 2007;212(4–5):253–266.
 25. Paidassi H, Tacnet-Delorme P, Garlatti V, et al. C1q binds phosphatidyl-
serine and likely acts as a multiligand-bridging molecule in apoptotic cell 
recognition. J Immunol. 2008;180(4):2329–2338.
 26. Varsano S, Frolkis I, Ophir D. Expression and distribution of cell-mem-
brane complement regulatory glycoproteins along the human respiratory 
tract. Am J Respir Crit Care Med. 1995;152(3):1087–1093.
 27. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitu-
mor immune response by complement. Nat Immunol. 2008;9(11):1225–1235.
 28. Nunez-Cruz S, Gimotty PA, Guerra MW, et  al. Genetic and phar-
macologic inhibition of complement impairs endothelial cell func-
tion and ablates ovarian cancer neovascularization. Neoplasia. 
2012;14(11):994–1004.
 29. Villanueva J, Shaffer DR, Philip J, et  al. Differential exoprotease activi-
ties confer tumor-specific serum peptidome patterns. J Clin Invest. 
2006;116(1):271–284.
 30. Boeri M, Verri C, Conte D, et  al. MicroRNA signatures in tissues and 
plasma predict development and prognosis of computed tomography 
detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–3718.
Funding
This work was supported by UTE project CIMA; the Spanish Government (grant 
numbers ISCIII-RTICC RD06/0020/0066, RD06/0020/1024, RD12/0036/0025, 
RD12/0036/0040, RD12/0036/0062, PI08/0923, PI10/01652, PI10/00166, 
and PI11/00618); the European Regional Development Fund; the European 
Community’s Seventh Framework Programme (HEALTH-F2-2010-258677-
CURELUNG); and the Early Detection Research Network from the National 
Cancer Institute (grant number U01 CA152662). This work was supported 
(in part) by a grant (RD12/0036/XXXX) from Red Temática de Investigación 
Cooperativa en Cáncer, Instituto de Salud Carlos III, Spanish Ministry of 
Economy and Competitiveness & European Regional Development Fund “Una 
manera de hacer Europa”.
Notes
D. Ajona, L. Corrales, L. M. Montuenga, and R. Pio were responsible for the 
study conception and design. L. M. Montuenga and R. Pio supervised the study. 
J. L. Perez-Gracia, M. D. Lozano, W. Torre, J. P. de-Torres, E. Jantus-Lewintre, 
C.  Camps, and J.  J. Zulueta provided study material and patients. D.  Ajona, 
L. Corrales, M. J. Pajares, and J. Agorreta acquired the data. D. Ajona, L. Corrales, 
M.  J. Pajares, J.  Agorreta, P.  P. Massion, L.  M. Montuenga, and R.  Pio were 
responsible for the analysis and interpretation of data. D. Ajona, J. Agorreta, and 
R. Pio did the statistical analysis. D. Ajona, L. M. Montuenga, and R. Pio drafted 
the manuscript. L. Corrales, J. L. Perez-Gracia, M. D. Lozano, W. Torre, P. P. 
Massion, J. P. de-Torres, E. Jantus-Lewintre, C. Camps, and J. J. Zulueta critically 
reviewed the manuscript. All authors approved the final version of the manuscript.
The study sponsors were not involved in the design of the study; the collec-
tion, analysis, and interpretation of the data; the writing of the manuscript; or the 
decision to submit the manuscript for publication.
We thank the Spanish Lung Cancer Group; Dr John D. Minna, who kindly 
provided the immortalized human bronchial epithelial cells; Dr Santiago 
Rodriguez de Cordoba, who critically read the manuscript; and Amaya Lavin, 
Usua Montes, Ana Moreno, Ana Remirez, and Cristina Sainz for technical 
support.
Affiliations of authors: Division of Oncology, Center for Applied Medical 
Research, Pamplona, Spain (DA, MJP, LC, JA, LMM, RP); Department of 
Histology and Pathology (MJP, JA, LMM) and Department of Biochemistry 
and Genetics (RP) School of Medicine, University of Navarra, Pamplona, 
Spain; Department of Oncology (JLP), Department of Pathology (MDL), 
Department of Thoracic Surgery (WT), Department of Pulmonary Medicine 
(JPdT, JJZ) Clínica Universidad de Navarra, Pamplona, Spain; Thoracic 
Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical 
Center, Nashville, TN (PPM); Department of Medicine, University of 
Valencia, Valencia, Spain (CC); Department of Medical Oncology, Hospital 
General Universitario de Valencia, Valencia, Spain (CC); Molecular Oncology 
Laboratory, Fundación para la Investigación del Hospital General Universitario 
de Valencia, Valencia, Spain (EJL).
